公开(公告)号：US10278926B2

公开(公告)日：2019-05-07

申请号：US15525281

申请日：2015-11-11

Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE ,  OSAKA MEDICAL COLLEGE ,  Masaaki Ii ,  Yasuhiko Tabata

Inventor： Masaaki Ii ,  Yasuhiko Tabata

IPC: A61K9/51 ,  A61K45/00 ,  A61K47/34 ,  A61K9/16 ,  A61K31/366 ,  A61K35/12 ,  A61K47/69 ,  A61K9/14 ,  A61K35/34 ,  A61K39/00

Abstract: A preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer is disclosed. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. A stem cell with an enhanced function is disclosed. The stem cell takes up and contains the statin-encapsulated nanoparticle.

公开(公告)号：US09463262B2

公开(公告)日：2016-10-11

申请号：US13882857

申请日：2011-11-01

Applicant: Yasuhiko Tabata ,  Shingo Kawabata

Inventor： Yasuhiko Tabata ,  Shingo Kawabata

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/04 ,  A61L27/22 ,  A61L27/38 ,  A61L27/54

CPC classification number: A61L27/22 ,  A61L27/227 ,  A61L27/3804 ,  A61L27/54 ,  A61L2300/25 ,  A61L2300/252 ,  A61L2420/02

Abstract: An object of the present invention is to provide a cell-adhesive material for biological tissues, in which the surface of a material for biological tissues (particularly metallic material) is modified strongly with a large amount of a cell-adhesive artificial peptide (P) that retains a biological activity.The present invention provides a cell-adhesive material for biological tissues including a cell-adhesive artificial peptide (P) and a material for biological tissues, wherein the cell-adhesive artificial peptide (P) is immobilized on the surface of the material for biological tissues through an electrochemical reaction. The cell-adhesive artificial peptide (P) is preferably a peptide (P1) that is synthesized by a genetic recombinant microorganism and has at least one cell-adhesive minimal amino acid sequence (X) in one molecule. The number of the cell-adhesive minimal amino acid sequences (X) in one molecule of the polypeptide (P1) is preferably 3 to 50.

Abstract translation: 本发明提供一种用于生物组织的细胞粘合剂材料，包括细胞粘附人造肽（P）和生物组织的材料，其中细胞粘附人造肽（P）固定在生物组织材料的表面上 通过电化学反应。 细胞粘合剂人造肽（P）优选为由遗传重组微生物合成并在一个分子中具有至少一个细胞粘附性最小氨基酸序列（X）的肽（P1）。 多肽（P1）的一个分子中的细胞粘附性最小氨基酸序列（X）的数目优选为3〜50。

公开(公告)号：US08895508B2

公开(公告)日：2014-11-25

申请号：US13386844

申请日：2009-07-24

Applicant: Yasuhiko Tabata ,  Shigeru Kinoshita ,  Noriko Koizumi ,  Yuji Sakamoto ,  Naoki Okumura ,  Hiroaki Takahashi

Inventor： Yasuhiko Tabata ,  Shigeru Kinoshita ,  Noriko Koizumi ,  Yuji Sakamoto ,  Naoki Okumura ,  Hiroaki Takahashi

IPC: A61K38/18 ,  A61K9/00 ,  A61K9/06 ,  A61K47/42

CPC classification number: A61K38/1825 ,  A61K9/0048 ,  A61K9/06 ,  A61K47/42

Abstract: The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on gelatin hydrogel. Therefore, the proliferation of corneal endothelium cells can be accelerated persistently by administration of a preparation containing the bFGF sustained-release gelatin hydrogel particles into the anterior chamber, and diseases relating to corneal endothelium damage can be treated.

Abstract translation: 本发明的目的在于提供角膜内皮细胞增殖促进剂和与角膜内皮损伤相关的疾病的治疗剂，其被施用于前房。 通过形成bFGF缓释明胶水凝胶颗粒，其中bFGF携带在明胶水凝胶上，以持续的方式释放bFGF。 因此，可以通过将含有bFGF缓释明胶水凝胶颗粒的制剂给予前房来持续加速角膜内皮细胞的增殖，并且可以治疗与角膜内皮损伤有关的疾病。

公开(公告)号：US08771734B2

公开(公告)日：2014-07-08

申请号：US10549695

申请日：2004-03-15

Applicant: Yasuhiko Tabata

Inventor： Yasuhiko Tabata

IPC: A61K9/22

CPC classification number: A61K9/06

Abstract: A sustained-release preparation is provided which comprises a drug and a bioabsorbable polymer hydrogel, wherein a concentration gradient of the drug is formed in the hydrogel. Also disclosed is a method of sustained release of a drug in vivo using the sustained-release preparation of the invention. The directionality of the drug release may be controlled by employing the sustained-release preparation of the invention. The sustained-release preparation of the invention is particularly useful as an anti-cancer agent.

Abstract translation: 提供了一种持续释放制剂，其包含药物和生物可吸收聚合物水凝胶，其中在水凝胶中形成药物的浓度梯度。 还公开了使用本发明的缓释制剂在体内持续释放药物的方法。 可以通过使用本发明的缓释制剂来控制药物释放的方向性。 本发明的缓释制剂作为抗癌剂是特别有用的。

公开(公告)号：US08435953B2

公开(公告)日：2013-05-07

申请号：US12741694

申请日：2008-11-06

Applicant: Yasuhiko Tabata

Inventor： Yasuhiko Tabata

IPC: A61K38/18 ,  A61K8/65 ,  A61K9/52 ,  C07K14/525

CPC classification number: A61K47/42 ,  A61K9/0002 ,  A61K9/0019 ,  A61K9/0024 ,  A61K38/195

Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.

公开(公告)号：US20120034694A1

公开(公告)日：2012-02-09

申请号：US13204324

申请日：2011-08-05

Applicant: Fumihiko Kitagawa ,  Takafumi Imaizumi ,  Shunsuke Takei ,  Itsuki Yamamoto ,  Yasuhiko Tabata

Inventor： Fumihiko Kitagawa ,  Takafumi Imaizumi ,  Shunsuke Takei ,  Itsuki Yamamoto ,  Yasuhiko Tabata

IPC: C12N5/077 ,  C12M3/00

CPC classification number: C12N5/0068 ,  C12N5/0663 ,  C12N2533/14 ,  C12N2535/00

Abstract: The present invention relates to a cell culture support for culturing mesenchymal stem cells, which includes en upper surface including a plurality of wells, in which the upper surface has a root mean square roughness Rq of 100 to 280 nm and a linear density of 1.6 to 10 per 1 μm length.

Abstract translation: 本发明涉及培养间充质干细胞的细胞培养支持体，其包括上表面，包括多个孔，其中上表面的均方根粗糙度Rq为100〜280nm，线密度为1.6〜 每1μm长度10个。

公开(公告)号：US20100267612A1

公开(公告)日：2010-10-21

申请号：US12741694

申请日：2008-11-06

Applicant: Yasuhiko Tabata

Inventor： Yasuhiko Tabata

IPC: A61K38/02 ,  A61P9/10 ,  A61P19/08

CPC classification number: A61K47/42 ,  A61K9/0002 ,  A61K9/0019 ,  A61K9/0024 ,  A61K38/195

Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.

Abstract translation: 本发明的目的是提供含有SDF-1的缓释组合物。 本发明提供了含有（1）SDF-1和（2）含有具有羧基和/或磺基的改性明胶的水凝胶的缓释组合物。 由于组合物可以以持续的方式释放能够促进体内血管祖细胞积聚的趋化因子SDF-1，因此可用于治疗和/或抑制缺血性疾病或骨疾病症状进展， 作为各种制剂中的药物制剂。

公开(公告)号：US20090022802A1

公开(公告)日：2009-01-22

申请号：US12182809

申请日：2008-07-30

Applicant: Yasuhiko Tabata ,  Masashi Komeda

Inventor： Yasuhiko Tabata ,  Masashi Komeda

IPC: A61K9/00 ,  A61K38/18 ,  A61P9/00

CPC classification number: A61K9/0019 ,  A61K38/1833 ,  A61K47/42

Abstract: The present invention provides a cardiomyopathy therapeutic agent that contains hepatocyte growth factor (HGF) and gelatin hydrogel, and gradually releases HGF, which is useful in treating cardiomyopathy.

Abstract translation: 本发明提供含有肝细胞生长因子（HGF）和明胶水凝胶的心肌病治疗剂，逐渐释放可用于治疗心肌病的HGF。

公开(公告)号：US07476648B1

公开(公告)日：2009-01-13

申请号：US10111483

申请日：2000-10-26

Applicant: Yasuhiko Tabata ,  Susumu Miyamoto

Inventor： Yasuhiko Tabata ,  Susumu Miyamoto

IPC: A61K38/00 ,  A61K38/18

CPC classification number: A61L31/16 ,  A61B17/12022 ,  A61B17/12113 ,  A61B17/12186 ,  A61B17/1219 ,  A61L31/145 ,  A61L2300/414 ,  A61L2300/418 ,  A61L2430/36

Abstract: According to the present invention, a vessel embolic material comprising a hydrogel containing a cell growth factor, which is applicable to embolic operations for various vascular disorders, excellent in high adaptability to a living body, can be easily handled, ensures the occlusion of the affected part and can maintain the occlusion for a long time, and a method of treatment using the same can be provided.

Abstract translation: 根据本发明，可以容易地处理包含含有细胞生长因子的水凝胶的血管栓塞材料，其适用于对生物体的高适应性优异的各种血管疾病的栓塞手术，确保受影响的 并且可以长期保持闭塞，并且可以提供使用其的治疗方法。

公开(公告)号：US20080318863A1

公开(公告)日：2008-12-25

申请号：US12136797

申请日：2008-06-11

Applicant: Yasuhiko Tabata ,  Masashi Komeda

Inventor： Yasuhiko Tabata ,  Masashi Komeda

IPC: A61K38/39 ,  A61P9/10

CPC classification number: A61K38/014 ,  A61K9/0019 ,  A61K38/1825 ,  A61K38/1833 ,  A61K38/1866 ,  A61K47/42 ,  A61K2300/00

Abstract: The present invention provides a ischemia therapeutic agent that contains vascularization induction factor and gelatin hydrogel, and gradually releases vascularization induction factor, which is useful in treating ischemia accompanying peripheral circulatory disorders etc. encountering as complications of arteriosclerosis obliterans, Buerger's disease, diabetes and collagen disease.

Abstract translation: 本发明提供含有血管形成诱导因子和明胶水凝胶的缺血治疗剂，并逐渐释放血管形成诱导因子，其可用于治疗伴随周围循环障碍等的缺血，其为闭塞性动脉硬化症，Buerger氏病，糖尿病和胶原性疾病的并发症 。